Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant amount » significant impact (Expand Search)
significant level » significance level (Expand Search), significance levels (Expand Search), significant gender (Expand Search)
Showing 2,541 - 2,560 results of 21,342 for search '(( ((significant amount) OR (significant level)) decrease ) OR ( significant decrease decrease ))', query time: 0.62s Refine Results
  1. 2541
    One-way ANCOVA results for Task 2. The bold values highlight statistically significant results of Task 2.

    One-way ANCOVA results for Task 2. The bold values highlight statistically significant results of Task 2. by Mucahit Gemici (21519313)

    Published 2025
    Save to List
    Saved in:
  2. 2542
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 2543
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 2544
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 2545
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 2546
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 2547
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 2548
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 2549
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 2550
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 2551
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 2552
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 2553
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 2554
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 2555
    Recruitment flow diagram of the current study.

    Recruitment flow diagram of the current study. by Somayeh Momenyan (10111603)

    Published 2025
    “…HRQoL outcome was assessed with the 5-level version of the EuroQol (EQ-5D-5L) instrument at baseline (pre-injury) and at 2, 4, 6, and 12 months post-injury. …”
    Save to List
    Saved in:
  16. 2556
    Myeloid knockout <i>VANGL2</i> exacerbates the progression of DSS-induced colitis in mice.

    Myeloid knockout <i>VANGL2</i> exacerbates the progression of DSS-induced colitis in mice. by Huaji Jiang (16907514)

    Published 2025
    Save to List
    Saved in:
  17. 2557
    CaSki cells functionally express VDR and RXR.

    CaSki cells functionally express VDR and RXR. by Euclides Avila (41023)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 2558
    Biological processes activated and suppressed, along with associated genes, induced by calcitriol treatment in CaSki cervical cancer cells.

    Biological processes activated and suppressed, along with associated genes, induced by calcitriol treatment in CaSki cervical cancer cells. by Euclides Avila (41023)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 2559
    Calcitriol inhibits CaSki cell migration and suppresses MMP7 and MMP13 gene expression.

    Calcitriol inhibits CaSki cell migration and suppresses MMP7 and MMP13 gene expression. by Euclides Avila (41023)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 2560
    Differentially expressed mature microRNAs in CaSki cells modulated by calcitriol, with fold change thresholds of ≥ 1.5 or ≤ -1.5.

    Differentially expressed mature microRNAs in CaSki cells modulated by calcitriol, with fold change thresholds of ≥ 1.5 or ≤ -1.5. by Euclides Avila (41023)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: